Literature DB >> 35554644

Value of native T1 mapping in the prediction of major adverse cardiovascular events in hemodialysis patients.

Le Qin1, Shengjia Gu1, Ruijie Xiao1, Peng Liu1, Fuhua Yan1, Haijin Yu2, Wenjie Yang3.   

Abstract

OBJECTIVES: This study aimed to evaluate the association of myocardial characterization by native T1 mapping using cardiac MR (CMR) with the incidence of major adverse cardiovascular event (MACE) in end-stage renal dysfunction (ESRD) patients on hemodialysis.
METHODS: A total of 52 ESRD patients and 52 healthy individuals were prospectively recruited between June 2017 and June 2018. ESRD patients underwent CMR examinations post-hemodialysis for the evaluation of cardiac function and global native T1 mapping. Demographics, serum biomarkers, and coronary artery calcification were collected. MACE including all-caused death, and new onset of myocardial infarction, heart failure leading to hospitalization, fatal arrhythmia, and cardiac arrest was set as the endpoint.
RESULTS: During a median follow-up of 38.0 months, 13 patients (25.0%) reached the endpoints. Global native T1 mapping in patients on hemodialysis was significantly higher compared with that of healthy individuals (1280.3 ms ± 45.3 vs. 1238.2 ms ± 31.1, p < 0.001). In the univariate Cox regression analysis, global native T1 mapping (HR [hazard ratios]: 1.887, 95% CI [confidence interval]: 1.302-2.736, p = 0.001) was associated with the prediction of MACE. Multivariate Cox regression analysis demonstrated that global native T1 mapping (HR: 1.580, 95% CI: 1.112-2.244, p = 0.011) and age (HR: 1.088, 95% CI: 1.032-1.146, p = 0.002) were associated with the incidence of MACE after adjusting for other conventional risk factors.
CONCLUSIONS: Global native T1 mapping by CMR can potentially become a novel predictor of MACE in ESRD patients on hemodialysis, providing additional prognostic values over conventional risk factors. However, this conclusion should be validated in a larger sample size of hemodialysis patients. KEY POINTS: • Global native T1 mapping was significantly higher in ESRD patients on hemodialysis compared with that of normal controls. • Global native T1 mapping was associated with myocardial enzymes, myocardial hypertrophy, coronary calcification, and cardiac function. • Global native T1 mapping value was independently predictive of MACE in hemodialysis patients, providing additional prognostic values over conventional risk factors.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Biomarkers; Kidney failure, chronic; Magnetic resonance; Myocardium; Renal dialysis

Mesh:

Year:  2022        PMID: 35554644     DOI: 10.1007/s00330-022-08839-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  48 in total

Review 1.  Hemodialysis-induced cardiovascular disease.

Authors:  Shadi Ahmadmehrabi; W H Wilson Tang
Journal:  Semin Dial       Date:  2018-04-06       Impact factor: 3.455

Review 2.  The heart and vascular system in dialysis.

Authors:  Christoph Wanner; Kerstin Amann; Tetsuo Shoji
Journal:  Lancet       Date:  2016-05-22       Impact factor: 79.321

Review 3.  Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations.

Authors:  Srisakul Chirakarnjanakorn; Sankar D Navaneethan; Gary S Francis; W H Wilson Tang
Journal:  Int J Cardiol       Date:  2017-01-04       Impact factor: 4.164

Review 4.  Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease.

Authors:  Peter A McCullough; Christopher T Chan; Eric D Weinhandl; John M Burkart; George L Bakris
Journal:  Am J Kidney Dis       Date:  2016-11       Impact factor: 8.860

Review 5.  Worldwide access to treatment for end-stage kidney disease: a systematic review.

Authors:  Thaminda Liyanage; Toshiharu Ninomiya; Vivekanand Jha; Bruce Neal; Halle Marie Patrice; Ikechi Okpechi; Ming-hui Zhao; Jicheng Lv; Amit X Garg; John Knight; Anthony Rodgers; Martin Gallagher; Sradha Kotwal; Alan Cass; Vlado Perkovic
Journal:  Lancet       Date:  2015-03-13       Impact factor: 79.321

6.  Development and validation of cardiovascular risk scores for haemodialysis patients.

Authors:  Stefan D Anker; Iain A Gillespie; Kai-Uwe Eckardt; Florian Kronenberg; Sharon Richards; Tilman B Drueke; Peter Stenvinkel; Ronald L Pisoni; Bruce M Robinson; Daniele Marcelli; Marc Froissart; Jürgen Floege
Journal:  Int J Cardiol       Date:  2016-04-20       Impact factor: 4.164

Review 7.  Chronic kidney disease: global dimension and perspectives.

Authors:  Vivekanand Jha; Guillermo Garcia-Garcia; Kunitoshi Iseki; Zuo Li; Saraladevi Naicker; Brett Plattner; Rajiv Saran; Angela Yee-Moon Wang; Chih-Wei Yang
Journal:  Lancet       Date:  2013-05-31       Impact factor: 79.321

Review 8.  Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices.

Authors:  Bruce M Robinson; Tadao Akizawa; Kitty J Jager; Peter G Kerr; Rajiv Saran; Ronald L Pisoni
Journal:  Lancet       Date:  2016-05-22       Impact factor: 79.321

Review 9.  The Complement System in Dialysis: A Forgotten Story?

Authors:  Felix Poppelaars; Bernardo Faria; Mariana Gaya da Costa; Casper F M Franssen; Willem J van Son; Stefan P Berger; Mohamed R Daha; Marc A Seelen
Journal:  Front Immunol       Date:  2018-01-25       Impact factor: 7.561

Review 10.  Imaging of Myocardial Fibrosis in Patients with End-Stage Renal Disease: Current Limitations and Future Possibilities.

Authors:  M P M Graham-Brown; A S Patel; D J Stensel; D S March; A-M Marsh; J McAdam; G P McCann; J O Burton
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.